相似文献
1
A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules.
Bioorg Med Chem Lett. 2008 Apr 15;18(8):2679-83. doi: 10.1016/j.bmcl.2008.03.022. Epub 2008 Mar 10.
2
A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Nucl Med Biol. 2016 Sep;43(9):566-576. doi: 10.1016/j.nucmedbio.2016.06.004. Epub 2016 Jun 28.
3
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Bioconjug Chem. 2008 Aug;19(8):1579-87. doi: 10.1021/bc800110y. Epub 2008 Jul 12.
4
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1368-76. doi: 10.1007/s00259-009-1370-z. Epub 2010 Feb 13.
5
Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.
J Med Chem. 2007 Sep 20;50(19):4759-65. doi: 10.1021/jm070657w. Epub 2007 Aug 29.
6
Preparation of Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A″-DTPA as bifunctional chelators.
J Labelled Comp Radiopharm. 2019 Apr;62(4):158-165. doi: 10.1002/jlcr.3707. Epub 2019 Feb 17.
7
AAZTA-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for Lu-labeling of monoclonal antibodies under mild conditions.
Nucl Med Biol. 2021 May-Jun;96-97:80-93. doi: 10.1016/j.nucmedbio.2021.03.007. Epub 2021 Mar 26.
8
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Nucl Med Biol. 2011 Nov;38(8):1119-27. doi: 10.1016/j.nucmedbio.2011.05.003. Epub 2011 Jul 7.
9
Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.
J Med Chem. 2006 Jul 13;49(14):4297-304. doi: 10.1021/jm060317v.
10
Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.
Br J Pharmacol. 2009 Aug;157(8):1541-8. doi: 10.1111/j.1476-5381.2009.00327.x.
引用本文的文献
1
First-in-human phase 0 study of In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.
J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.
2
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
3
Strategies for the preparation of bifunctional gadolinium(III) chelators.
Curr Org Synth. 2011 Aug 1;8(4):535-565. doi: 10.2174/157017911796117250.
4
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S57-68. doi: 10.1007/s00259-011-1771-7. Epub 2011 Mar 11.
5
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Bioconjug Chem. 2008 Aug;19(8):1579-87. doi: 10.1021/bc800110y. Epub 2008 Jul 12.
本文引用的文献
1
Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.
J Med Chem. 2007 Sep 20;50(19):4759-65. doi: 10.1021/jm070657w. Epub 2007 Aug 29.
2
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
Clin Cancer Res. 2007 Mar 15;13(6):1926-35. doi: 10.1158/1078-0432.CCR-06-2300.
3
Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.
J Med Chem. 2006 Jul 13;49(14):4297-304. doi: 10.1021/jm060317v.
4
Arming antibodies: prospects and challenges for immunoconjugates.
Nat Biotechnol. 2005 Sep;23(9):1137-46. doi: 10.1038/nbt1141.
5
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S.
6
Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.
Clin Cancer Res. 2004 Dec 1;10(23):7834-41. doi: 10.1158/1078-0432.CCR-04-1226.
7
Antibody-targeted radiation cancer therapy.
Nat Rev Drug Discov. 2004 Jun;3(6):488-99. doi: 10.1038/nrd1413.
8
Targeting of radio-isotopes for cancer therapy.
Cancer Biol Ther. 2004 Apr;3(4):361-70. doi: 10.4161/cbt.3.4.790. Epub 2004 Apr 3.
9
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Semin Nucl Med. 2004 Jan;34(1 Suppl 1):4-9. doi: 10.1053/j.semnuclmed.2003.11.002.
10
Advancing role of radiolabeled antibodies in the therapy of cancer.
Cancer Immunol Immunother. 2003 May;52(5):281-96. doi: 10.1007/s00262-002-0348-5. Epub 2003 Mar 11.
Zotero 插件